Injectable Cultured Bone Marrow–Derived Mesenchymal Stem Cells in Varus Knees With Cartilage Defects Undergoing High Tibial Osteotomy: A Prospective, Randomized Controlled Clinical Trial With 2 Years' Follow-up

Wong, Keng Lin; Lee, Kevin Boon Leng; Tai, Bee Choo; Law, Ping; Lee, Eng Hin; Hui, James

doi:10.1016/j.arthro.2013.09.074

Cited by 334 publications

(284 citation statements)

References 25 publications

Supporting

Mentioning

281

Contrasting

Unclassified

Order By: Relevance

“…Besides, BM-MSCs are relatively primitive cells, whose immunogenicity is weak and can inhibit the mixed lymphocyte reaction. However, previous studies also reported the clinical application of BM-MSCs is not matched with donor, host immune rejection or graft versus host reaction (50)(51)(52). Moreover, allogeneic bone marrow transplantation of mesenchymal stem cells in severe idiopathic aplastic anemia patients have also been shown to improve the effect of bone marrow stromal function (53,54).…”

Section: Remaining Problems and Future Directionsmentioning

confidence: 99%

Into the eyes of bone marrow-derived mesenchymal stem cells therapy for myocardial infarction and other diseases

Li¹,

Qu²

2017

Stem Cell Investig.

View full text Add to dashboard Cite

Applications of bone marrow-derived mesenchymal stem cells (BM-MSCs) have been documented for diseases occur in the sports system, the central nervous system, the cardiovascular system etc. However, poor viability of donor stem cells after transplantation limits their therapeutic efficiency. Although the autophagy theory has been reported, the underlying mechanisms are still poorly understood. Isolation and culture methods of mesenchymal stem cells are currently concentrate on four ways. Overall, BM-MSCs have both important research significance and clinical application value in cell replacement therapy, gene therapy and reconstruction of tissues as well as organs especially for myocardial infarction (MI). In this article, we review the biological characteristics of BM-MSCs and its research progress especially in MI. bone marrow which has aroused people's interest (1,4,5). Furthermore, BM-MSCs can act as support hematopoietic cells, promoting the growth of hematopoietic stem cells. Above all, BM-MSCs have broad application prospects in tissue engineering, cell transplantation and gene therapy because of the advantages of easy separation, amplification and easy operation in vitro and in vivo (6)(7)(8)(9). Taken together, BM-MSCs have important research significance and clinical application value in cell replacement therapy, gene therapy and tissue regeneration. In this article we review the latest progress, limitation as well as clinical application of BMMSCs. Isolation of BM-MSCsBM-MSCs are obtained mainly from bone marrow aspiration, while human BM-MSCs are generally drawn from the anterior superior iliac spine (10). They are also available from the tibia, femur, sternum, lumbar spine. The acquisition sites of BM-MSCs in large animals are the same as humans, however, rabbits' BM-MSCs need to be extracted in the middle of the tibia or femur bone marrow (11-13). The proportion of BM-MSCs nucleated cell population accounts for less than 0.0001% of them, however they can easily be isolated and expanded by using certain cell culture techniques (10). Stro-1 monoclonal antibody is usually used to isolate BM-MSCs which grow by attaching to the wall in laminin adhesion culture plate with low concentration of serum and CD45-/A-glycoproteins (14). In the past, BM-MSCs isolation methods were mainly concentrated on density gradient centrifugation method, differential adherence screening method, flow cytometry sorting method as well as immune beads method (15). However, high purity of BM-MSCs cannot be obtained by the four kinds of separation methods as described above. Nowadays, selecting the appropriate factor based on different reactivity of BM-MSCs to growth factors, to stimulate the proliferation, obtaining a higher proportion the mesenchymal stem cells has been regarded as a more accurate isolation method. Meanwhile, the new method of using 3 microns diameter plastic petri dish to screen BMMSCs, whose homogeneity are greater than 98%, with capacity of proliferation, self-renewal and have the potential to diff...

show abstract

Section: Remaining Problems and Future Directionsmentioning

confidence: 99%

Into the eyes of bone marrow-derived mesenchymal stem cells therapy for myocardial infarction and other diseases

Li¹,

Qu²

2017

Stem Cell Investig.

View full text Add to dashboard Cite

show abstract

“…Furthermore, research on stem-cell transplantation suggests that the results largely depend on synchronizing donor cells into the G0/G1 phase, and the fraction of mononuclear cells (MNC) in G0 phase is very low (1:10.000 to 1:1.000.000). Cell culture not only induces cell cycle synchronization at G0/G1 stage of mesenchymal stem cells but also facilitates reaching a yield of several millions MSC in a few weeks [54].…”

Section: Discussionmentioning

confidence: 99%

Treatment of Knee Osteoarthritis with Autologous Expanded Bone Marrow Mesenchymal Stem Cells: 50 Cases Clinical and MRI Results at One Year Follow-Up

R¹,

Munar²,

F³

et al. 2015

J Stem Cell Res Ther

View full text Add to dashboard Cite

“…Magnetic resonance imaging (MRI) scans performed one year after the surgical intervention showed significantly better Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) scores for the cell-recipient group than the microfracture alone group (28 patients) [76]. In a pilot study of 12 OA patients with intra-articular injection of 40 million autologous expanded BM-MSCs, the patients showed a large improvement in algofunctional indices by one year, and MRI scanning exhibited a 27% decrease in poor cartilage areas with improvement of cartilage quality in 11 of the 12 patients [77].…”

Section: Msc Therapy For Oamentioning

confidence: 99%

Treatment of osteoarthritis with mesenchymal stem cells

Wang

Cao

2014

Sci. China Life Sci.

View full text Add to dashboard Cite

Osteoarthritis (OA) is one of the most prevalent joint diseases with prominent symptoms affecting the daily life of millions of middle aged and elderly people. Despite this, there are no successful medical interventions that can prevent the progressive destruction of OA joints. The onset of pathological changes in OA is associated with deviant activity of mesenchymal stem cells (MSCs), the multipotent precursors of connective tissue cells that reside in joints. Current therapies for OA have resulted in poor clinical outcomes without repairing the damaged cartilage. Intra-articular delivery of culture-expanded MSCs has opened new avenues of OA treatment. Pre-clinical and clinical trials demonstrated the feasibility, safety, and efficacy of MSC therapy. The Wnt/β-catenin, bone morphogenetic protein 2, Indian hedgehog, and Mitogen-activated protein kinase signaling pathways have been demonstrated to be involved in OA and the mechanism of action of MSC therapies. osteoarthritis, mesenchymal stem cells, intra-articular delivery Citation:Wang W, Cao W. Treatment of osteoarthritis with mesenchymal stem cells.

show abstract

Injectable Cultured Bone Marrow–Derived Mesenchymal Stem Cells in Varus Knees With Cartilage Defects Undergoing High Tibial Osteotomy: A Prospective, Randomized Controlled Clinical Trial With 2 Years' Follow-up

Cited by 334 publications

References 25 publications

Into the eyes of bone marrow-derived mesenchymal stem cells therapy for myocardial infarction and other diseases

Into the eyes of bone marrow-derived mesenchymal stem cells therapy for myocardial infarction and other diseases

Treatment of Knee Osteoarthritis with Autologous Expanded Bone Marrow Mesenchymal Stem Cells: 50 Cases Clinical and MRI Results at One Year Follow-Up

Treatment of osteoarthritis with mesenchymal stem cells

Contact Info

Product

Resources

About